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Abstract
Background: Intermittent preventive treatment with sulphadoxine-pyrimethamine (SP) is recommended for
reducing the risk of malaria in pregnancy and its consequences on mothers and babies (IPTp-SP). Indicators of
implementation and effects of IPTp-SP were collected in a rural clinic in Southern Senegal.
Methods:  Women seen routinely at the antenatal clinic (ANC) of a rural dispensary during 2000–2007.
Deployment of IPTp-SP started in January 2004. Inspection of antenatal and outpatient clinic registries of the
corresponding period.
Results: Between 1st January 2000 and 30th April 2007, 1,781 women of all gravitidities and parities attended the
ANC with 965 deliveries (606 and 398 respectively since 1st January 2004, when IPTp-SP was started.) 69% of
women were seen ≥ 3 times; 95% received at least one dose and 70% two doses of SP (from 61% in 2004 to 86%
in 2007). The first visit, first and second dose of SP occurred at a median week 20, 22 and 31. The probability of
receiving two doses was > 80% with ≥ 3 antenatal visits and a first dose of SP by week 20.
The prevalence of maternal malaria was low and similar pre- (0.7%) and during IPTp (0.8%). Effects on of low birth
weight (LBW, < 2.5 kg) were non-statistically significant. The prevalence of LBW was 10.8% pre- and 7.7% during
IPTp deployment (29% risk reduction, p = 0.12).
Unfavourable pregnancy outcomes numbered 72 (7.5% of pregnancies with known outcome), including 30
abortions and 42 later deaths (late foetal deaths, stillbirth, peri-natal) of which 13 with one or more malformations
(1.35% of all recorded deliveries).
Conclusion: The implementation of IPTp-SP was high. Early attendance to ANC favours completion of IPTp-SP.
The record keeping system in place is amenable to data extraction and linkage. A model was developed that
predicts optimal compliance to two SP doses, and could be tested in other settings. Maternal malaria was
infrequent and unaffected by IPTp-SP. The risk of LBW was lower during IPT implementation but the difference
was non-significant and could have other explanations.
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Background
Acquiring malaria during pregnancy contributes to mater-
nal illness and low birth weight (LBW, defined as birth
weight below 2,500 grammes, caused by either prematu-
rity or intra-uterine growth retardation), which consti-
tutes the greatest risk factor for neonatal and infant
mortality [1]. Intermittent Preventive Treatment with
drugs given routinely to pregnant women irrespective of
the presence of peripheral malaria parasites is part of the
World Health Organization (WHO) strategy to reduce the
risk of malaria in pregnancy and its consequences on the
mother and her baby (IPTp) [2].
The concept of IPT is based on clearance of the existing
(usually asymptomatic placental) infection and post-
treatment prophylaxis, i.e. the suppression of new infec-
tions over a variable period of time, depending on the
drug kinetics, blood levels and parasite susceptibility [3].
The only option currently available is sulphadoxine/
pyrimethamine (SP, 1,500 mg/75 mg). Two doses of SP,
one on the second trimester (after quickening) and one
on the third trimester of pregnancy, are recommended by
the WHO in areas of stable Plasmodium falciparum malaria
transmission with low (< 10%) HIV prevalence.
Two recent systematic reviews showed that (a) chemo-
prophylaxis or IPT reduces antenatal parasite prevalence
and placental malaria in women in all parity groups, and
improves birth weight and possibly perinatal death in
low-parity women [4]; (b) IPTp with SP remains effective
even in areas of parasite resistance to antifolate drugs,
though more doses may be required in the presence of
HIV coinfection [5]. However, the efficacy of this interven-
tion will likely be eroded by spreading parasite resistance
to SP and alternative drugs should be sought [3,6].
While implementing this policy, the WHO recommends
using outcome and impact indicators to document the
rate of implementation in control programmes and effects
of delivering IPTp on maternal and childhood health [2].
Relevant information was extracted from dispensary regis-
tries in the District of Oussouye, Casamance, Senegal, an
area of moderate malaria transmission.
Methods
Mlomp is a village of approximately 8,000 people in the
District of Oussouye, Casamance, south-western Senegal.
Malaria is meso-endemic in this area and increases during
the rainy season (July to September). The entomological
inoculation rate is 25 infected bites per person-year [7].
Malaria affects all ages, with a peak between 6–15 years of
age [8]. Until 2000, clinically suspected malaria was
treated with quinine or chloroquine; thereafter, a new
policy of treating parasitologically confirmed malaria
with a combination of artesunate and amodiaquine was
gradually introduced [9]. Contrary to chloroquine, qui-
nine, artesunate and amodiaquine [9,10], sulphadoxine-
pyrimethamine (SP) has not been used and no data on its
efficacy and safety exist.
The village dispensary, which is run by the St Joseph's con-
gregation, reports to the Oussouye medical district. The
dispensary has an antenatal clinic (ANC) and a maternity
clinic, in addition to its general dispensary activities. The
ANC runs once a week. Pregnancies which cannot be ade-
quately dealt with locally are referred to the district (Ous-
souye) or regional (Ziguinchor) hospital. A thin and thick
smear is done every time a patient presents with signs/
symptoms suggestive of malaria; for pregnant women,
this would happen either at the ANC or, if outside ANC
days, at the general clinic.
According to the policy in Senegal, every contact is
recorded both on the general register of the dispensary
and on the patient's health card. Each woman attending
the ANC is recorded in the pregnancy register and is given
an obstetric card, recording every visit and event. The
occurrence of malaria is recorded on the general register
and the women's health card. When she is next seen at the
ANC, this event is also recorded on the pregnancy register
and her obstetric card, and is also reported on a register of
complicated pregnancies, along with other notable or
untoward events. Deliveries are detailed on a delivery reg-
ister, and the pregnancy outcome reported on the general
pregnancy register and women's obstetric card.
The pregnancy, pregnancy complications and delivery reg-
isters of the dispensary covering the period 2000–2007
were inspected and information extracted and linked.
Data extraction concerned all women with a first antena-
tal visit by 30th April 2007 and the relevant pregnancy out-
come up until 15th August 2007.
Information on age, gravidity and parity of women, date
and number of visits and SP administration, pregnancy
outcome with date and birth weight was recorded. HIV
status is detected systematically unless the woman refuses
to consent and the result provided confidentially. If HIV
positive, the woman is referred for treatment to the Dis-
trict hospital. Other routine examinations at the first visit
are blood group, haemoglobin, Wasserman test for syph-
ilis and albumin in the urine.
The one-way ANOVA was used to compare birth weights
between years and number of IPTp doses. Continuous
data were assessed for normality using the Kolmogorov-
Smirnov test; if significant, data were log transformed and
analysed with a student 't' test, if normally distributed,
otherwise, with the Kruskal-Wallis test. Dichotomous var-
iables were analysed using the chi-squared or Fisher'sMalaria Journal 2008, 7:234 http://www.malariajournal.com/content/7/1/234
Page 3 of 11
(page number not for citation purposes)
exact test (Freeman-Halton if more than two categories),
if the expected counts were lower than five in any cell.
A logistic model was used to estimate the odds of receiv-
ing two against one SP dose. The baseline characteristics
of the women in the study [year of the first antenatal visit
(2004 as reference), age, gravidity and parity] were
entered in the model. A sub-analysis, restricted to the sub-
jects who had at least one SP dose was carried out with
explanatory variables recorded during the current preg-
nancy (number of antenatal visits, week of first antenatal
visit, week of the administration of the first and second SP
dose). Non significant variables were eliminated based on
the Wald test and the Likelihood Ratio test. Interactions
between parameters in the residual model were tested.
Points of equipoise were calculated from the logistic
model formula based on the estimated coefficients of the
parameters and their interactions.
All tests were two-tailed. A p-value < 0.05 was considered
statistically significant. Data were recorded in Excel® and
analysed with the statistical package SAS® System Version
9.1.3 (SAS Institute, Cary, NC, USA).
Results
Between 1st January 2000 and 30th April 2007, a total of
1,781 pregnant or suspected pregnant women made at
least one visit at the ANC of St Joseph's dispensary in
Mlomp, with 965 deliveries recorded (54%). The annual
attendance decreased from 319 in 2000 to 150 in 2006
(projections for 2007 are stable with respect to 2006) (Fig-
ure 1). Effective January 2004, the policy of systematically
offering women IPTp with sulphadoxine/pyrimethamine
(SP) was implemented. The breakdown for the period
2000–2003 was 1,175 women seen at least once at the
ANC and 567 deliveries (48% of the women seen at the
ANC) vs. 606 women and 398 deliveries (66%) for 2004–
2007 (chi-square p = 0.0001). Birth weight was available
overall for 904 babies (94% of the recorded deliveries),
529 (93%) and 375 (94%) for 2000–03 and 2004–07,
respectively.
Pregnancies seen at the antenatal clinic of Mlomp and deliveries recorded during 2000–2007* (*projected) Figure 1
Pregnancies seen at the antenatal clinic of Mlomp and deliveries recorded during 2000–2007* (*projected). 
2004 is the year of the beginning of the deployment of IPTp-SP.
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The 606 women attending the ANC from January 2004
had a median number of 3 (range 1–5) visits for each
pregnancy; 417 (69%) were seen ≥ 3 times (from 65% in
2004 to 78% in 2007). Over the period 2004–2007, 574
(95%) received at least one dose of SP and 422 (70%) two
doses (from 61% in 2004 to 86% in 2007). (Figure 2 and
Table 1). The attendees were women with a median age of
28 years [range 15–48] who had previously had between
0 and 14 pregnancies.
The median week of pregnancy at which the first ante-
natal visit occurred was week 20 (quartiles 16–24, n =
394), and was week 22 (19–25, n = 392) for the first dose
of SP and week 31 (27–33, n = 325) for the second dose.
Women who had two SP doses had their first visit on a
median week of 20.0 (quartiles 16.0–22.5, n = 325) com-
pared to 25.6 (18.8–29.0, n = 67) for those who had only
one dose (Figure 3). 221 (56%) women received SP
according to the WHO recommended IPTp schedule of
the first dose in the second trimester and the second dose
in the third trimester.
The logistic model based on the baseline characteristics of
the 567 women with at least one dose of SP showed that
the year in which the first visit occurred was significantly
associated with the probability of having two doses of SP
(p < 0.0001) and was significantly higher in 2006 and
2007 than in 2004 (OR (95%CI) = 2.97 (1.70–5.18) for
2006 and 5.76 (1.97–16.88) for 2007). Age, gravidity and
parity of the women had no influence.
When considering the 392 women with a recorded week
of first visit and first SP dose, the probability of having a
second dose of SP was significantly related to the number
of antenatal visits, the week of the first visit and the week
of first SP dose. The results of the logistic model are sum-
marized in Table 2.
The model does not estimate directly the Odds Ratio of
the parameters that are included in the interactions and
specific contrasts are estimated. Figure 4 depicts a simpli-
fied version of the model with selected weeks of first ante-
natal visit. For each and every week of first antenatal visit,
the probability of having two SP doses increased with the
number of visits. The model showed an interaction
between the week of first visit and the number of visits, so
that the occurrence of the first visit affected the probability
of having two SP doses differently depending on how
many visits took place thereafter.
Women with < 3 antenatal visits who had their first visit
early had a low probability of a second SP dose. The prob-
ability of a second SP dose increased in this group if the
first visit occurred later, but decreased for any week of the
first antenatal visit, if the first SP dose was given late.
All women who underwent three antenatal visits had the
same chance of a second SP dose if the first was given at
32 weeks (equipoise), whether the first antenatal visit was
early or late. Before this week the relative effects of the
week of first visit are similar to those described above for
< 3 visits; beyond this week, the order is inversed and
women who had their first visit early carried a higher
chance of having a second SP dose than those who were
seen later. The more the antenatal visits, the early the equi-
poise of probability distributions (23 in case of four visits,
15 if five). With the first SP dose on week 20 or before the
probability of a second SP dose remained > 80% for any
number of antenatal visits ≥ 3. (Figure 4)
Of the 606 women with a first antenatal visit between 1st
January 2004 and 30th April 2007, the outcomes of 398
deliveries are recorded (66%); 170 women were lost to
follow-up before delivery; in seven cases pregnancy was
not confirmed or did not progress (possibly including
early losses) and a record but no date exists for the
remaining 33. No significant differences were observed
for age, gravidity, parity, date of first visit or date of first SP
dose between women with a recorded delivery and the
others.
Overall, there were 28 unfavourable pregnancy outcomes
(7% of the 398 known outcomes) including 14 spontane-
ous abortions (miscarriage occurring by month 4.5 of
Table 1: Performance indicators of implementation of IPTp in Mlomp
2004 2005 2006 Jan-Apr 2007 total
women seen at ANC N 228 177 150 51 606
at least 3 antenatal visits N 147 120 110 40 417
% 64% 68% 73% 78% 69%
at least 1 dose of SP N 213 171 142 48 574
% 93% 97% 95% 94% 95%
2 doses of SP N 140 118 120 44 422
% 61% 67% 80% 86% 70%
recorded deliveries N 142 119 111 26 398
% 62% 67% 74% 51% 66%Malaria Journal 2008, 7:234 http://www.malariajournal.com/content/7/1/234
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pregnancy), 12 stillbirths or late fetal deaths and two peri-
natal deaths (these 14 deaths represent 3.5% of the 398
pregnancies with recorded outcome). Six of these also had
one or more obvious malformations (four anencephaly,
one anophthalmia and clubfoot, and one with clubfoot =
1.5% of the 398 recorded pregnancy outcomes). Birth
weight was available for 375 babies (median 3.1 kg, inter-
quartile range 2.8–3.4 kg). In addition, two women were
found to be HIV positive; they had uncomplicated preg-
nancies.
For comparison, 1,175 pregnancies and 567 deliveries
(529 with birth weights) were recorded prior to starting
IPTp during 2000–2003 with 44 unfavourable outcomes
(7.8% of the 567 known outcomes), of which 16 were
abortions, 21 stillbirths or late foetal deaths, and seven
perinatal deaths (these 28 cases represent a 5% mortality
for the 567 recorded pregnancy outcomes). Of these,
seven children had one or more malformations (1.2%),
namely two cases of hydrocephaly, one anencephaly
(with clubfoot), two with clubfoot, one spina bifida and
one case of respiratory tract malformation. The median
birth weight during this period was 3.0 kg (quartile 2.8–
3.4, n = 529). The observed difference in birth weight
between 200–2003 and 2004–2007 was not significant (p
= 0.43, Kruskall-Wallis)
Overall, 13 cases of parasitologically-confirmed maternal
malaria were recorded between 2000–2007 among these
women (one in 2000, four in 2001, one in 2002, two in
2003, one in 2004, one in 2005, two in 2006 and one in
2007). The incidence of malaria among women attending
the ANC was 0.7% during 2000–03 (pre institution of
IPTp) and 0.8% during the deployment of ITPp (Fisher 2-
tailed test p value = 0.8). This refers to all cases of malaria
in these women whether they occurred before their first
antenatal visit or while being followed at the ANC.
Of the eight cases of malaria in pregnancy which occurred
in women seen during 2000–2003, six had uncompli-
Rate of implementation of IPTp-SP and number of ANC visits in Mlomp between 2004–2007 Figure 2
Rate of implementation of IPTp-SP and number of ANC visits in Mlomp between 2004–2007.
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cated pregnancies and gave birth to normal babies
(malaria diagnosed between months 3 and 7), one who
had malaria in month 1 of pregnancy had a spontaneous
abortion on month 3, and one had malaria in month 9
and delivered a stillborn baby five days after diagnosis
and treatment. All were treated with parenteral quinine
and resolved. Of the five cases occurring after 2004,
malaria had occurred by month 4 of pregnancy and these
women (aged 17–41) received subsequently two doses of
SP. All were treated successfully and delivered healthy
babies at term weighing 2.7–3.8 Kg.
Low Birth Weight (LBW, defined as < 2.5 kg), was
recorded in 86/904 (9.5%) of children born during 2000–
2007, 29/375 (7.7%) of the neonates born to women seen
in 2004–2007 and 57/529 (10.8%) in those born pre-
2004 (Chi-square p-value = 0.12; OR [95%CI] = 0.69
[0.43–1.11]). The risk of LBW during 2004–07 was 29%
lower than in 2000–03. Birth weights and percentage of
LBWs by year are presented in Figure 5.
LBW was recorded in 22/309 (7.1%) of women who
received two doses of SP, compared to 7/63 (11.1%) for
one dose of SP, and 57/532 (10.7%) with no IPTp-SP
(Chi-square p = 0.16) (Table 3). A logistic model showed
no significant difference in the likelihood of LBW of being
on IPTp-SP vs. no treatment (p = 0.16); the OR [95%CI]
of LBW was 1.04 [0.45–2.40] with one SP dose and 0.61
Distribution of weeks of first antenatal visit for the women who received one or two SP doses Figure 3
Distribution of weeks of first antenatal visit for the women who received one or two SP doses.
Table 2: Results of linear combinations estimation from the logistic model of two vs. one SP doses.
Contrast Odds Ratio 95%CI Pr > ChiSq
1 visit increase in the number of antenatal visits 51.72 8.21 325.80 < .0001
1 week increase in the week of first visit 2.25 1.50 3.38 < .0001
1 week increase in the week of first SP dose 0.96 0.73 1.25 0.7443
5 week decrease for the first antenatal visit in women who had 3 to 5 visits 31.92 5.15 197.80 0.0002
5 week decrease for the first antenatal visit in women who had 0 to 2 visits 57.83 7.61 439.50 < .0001
5 week increase for the first SP dose in women who had a first antenatal visit at week 30 10.79 4.74 24.56 < .0001
5 week increase for the first SP dose in women who had a first antenatal visit at week 10 2.57 1.10 6.02 0.0300Malaria Journal 2008, 7:234 http://www.malariajournal.com/content/7/1/234
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Logistic model of the probability of receiving two SP doses for women with recorded delivery, date of first visit and SP admin- istration Figure 4
Logistic model of the probability of receiving two SP doses for women with recorded delivery, date of first visit 
and SP administration. The panels are for women with < 3 (A), 3 (B), 4 (C) and 5 (D) antenatal visits. For ease of reading 
only the calculated curves for weeks 9, 12, 18, 24, 30 and 36 of the first SP dose are presented. [Note: The point of equipoise 
is depicted as an example in panel C: when the number of antenatal visit is = 4, the probability of 2 SP doses is = 0.96 at the 
week of first SP dose = 23 when the week of first ANC is either 9, 12, 18, 24, 30 or 36].
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[0.36–1.03] for 2 SP doses vs. no SP. The year or period
(2000–2003 vs. 2004–2007) had no influence on the
likelihood of LBW (p = 0.72 and 0.097, respectively; p =
0.13, OR [95%CI] = 1.44 [0.90–2.3]).
Compared to no treatment, two doses of SP produced a
33.5% reduction in the prevalence of LBW (Absolute risk
reduction: 3.59% [-0.30%, 7.48%]).
The prevalence of LBW among paucigravidae (≤ 2 preg-
nancies) was 11.7% compared to 8% in multigravidae
(chi-square p = 0.4). Similarly, there was no difference in
LBW in primigravidae. A residual logistic model (n = 375)
showed that gravidity had a statistically non-significant
protective effect on the probability of having a LBW baby
(p = 0.38; OR [95%CI] = 0.93 [0.79–1.1]).
Discussion
This article describes what can be achieved under current
routine programmes in terms of both implementation of
interventions and data collection during pregnancy. It
shows that, with a good and motivated staff and compli-
ant attendees, pregnant women can be routinely followed
and IPTp can be effectively rolled out. The impact of IPTp
on maternal malaria and birthweight is less clear in this
setting.
Of the WHO recommended criteria to assess IPT in con-
trol programmes [2], implementation rate and birth
weight could be measured at this rural health centre in
Mlomp. In this area where malaria transmission is moder-
ate, artemisinin-based combination therapy (ACT) is
being deployed and HIV prevalence is low, the incidence
Birth weight of neonates during 2000–2007 Figure 5
Birth weight of neonates during 2000–2007. Boxplots (mean, median, interquartile range) with whiskers (x standard devi-
ation) and outliers. The dotted line represents defining a Low Birth Weight (LBW, birth weight < 2500 g). The % of newborn 
babies with LBW by year is displayed.Malaria Journal 2008, 7:234 http://www.malariajournal.com/content/7/1/234
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of malaria and LBW were not significantly affected forty
months into a high rate of implementation of IPTp-SP. It
should be pointed out that the incidence of clinical
malaria during pregnancy was very low both before and
during IPTp-SP and that placental malaria was not
assessed. However not significant and possibly influenced
by other factors, LBW was 29% lower while rolling out
IPTp-SP. It was also possible to collect information on
pregnancy outcomes and obvious defects in the babies, in
addition to maternal age, gravidity and parity.
The routine system in place in Senegal allows recording
events occurring during pregnancy. Data redundancy is an
inherent feature of this system (all or part of the informa-
tion may be recorded in different registers and cards),
which provides a degree of fault tolerance while making
record linkage and data collation somewhat time-con-
suming.
The rate of implementation of IPTp-SP in Mlomp was
high within few years of introduction of this practice;
overall, 70% of the women attending the ANC received
two doses of SP, increasing steadily from 61% on the first
year of introduction to reach 86% within just 40 months
of starting deployment. For reference, the initial target set
by Roll Back Malaria (RBM) for 2005 was 60% of preg-
nant women at risk of contracting malaria to be given che-
moprophylaxis or IPT [11]. In general, information on IPT
coverage is limited. Hill & Kazembe [12] collated and ana-
lysed data available up to 2004. At that time, the imple-
mentation of IPTp was much lower than the RBM target in
most countries. The coalition of Malaria in Pregnancy,
East & Southern Africa, MIPESA) reported in 2002 cover-
age rates for one SP dose ranging from 33% in Uganda to
93% in Malawi and for two doses from 24% in Uganda to
68% in Zambia [13]. More recently, Crawley et al [14]
report that now 34 of the 36 sub-Saharan African coun-
tries deemed eligible to IPTp deployment have adopted
and 22 are implementing IPTp-SP. IPTp coverage varies
and is difficult to quantify because delivery systems and
data collection methodologies differ. In Uganda, new
delivery approaches based on community mobilization
and training resource persons achieved 67.5% compli-
ance to two doses of SP, compared to 40% with the tradi-
tional approach [15].
Both Hill & Kazembe [12] and Crawley et al [14] also ana-
lyse the components and obstacles to the successful
deployment of IPTp. Access to ANC services is one such
element. In Mlomp, the median number of ANC visits
was three (ranging from one to five) per pregnancy, and
on average 69% of women were seen three times or more,
figures which are very similar to those reported in the
1999 Demographic Health Survey (DHS) for the country
(median 3.5 visits and 64% seen ≥ 3 times; for reference,
the WHO recommends four antenatal visits [16]). Of
note, the number of women with ≥ 3 visits in Mlomp
increased steadily from 64% in 2004 to 78% in 2007,
indicating improving performance. Overall, during the
same period 34% had ≥ 4 visits. In the same review, these
figures vary widely across Africa, from 2 to 4.8 visits and
from 10 to 72% seen ≥ 4 times. Timing of attendance is
also critical. In Mlomp, the median weeks women were
pregnant at the first visit was 20 (i.e. in their 5th month of
pregnancy), which is later than the 1999 Senegal DHS
data but within the range of the findings of the Hill &
Kazembe review. Of the other critical elements identified
by the review, here the turnout was high because antenatal
services are in demand in this population and the cus-
tomer is satisfied. The personnel at this Dispensary are
highly motivated to include IPTp in the daily routine of
ANC visits. The drug supply system is also good; there
were no drug stock-outs so that the process can go on
undisrupted.
According to WHO guidelines [2] and evidence from stud-
ies [5], programmes should aim for two doses of SP, while
ongoing trials are further testing this schedule against
monthly IPTp. The data from Mlomp indicate that, in gen-
eral in this setting, the earlier the administration of the
first dose of SP the higher the probability of receiving a
second dose. However, this cannot be interpreted without
taking into account the number of times a woman is seen
Table 3: Frequency of low birth weight (LBW) in newborns to women who received 2 doses, 1 dose of SP or no IPTp in Mlomp
Normal (=> 2.5 kg) LBW (< 2.5 kg) total
2 SP doses (2004–07) N 287 22 309
% 92.9% 7.1%
1 SP dose (2004–07) N 56 7 63
% 88.9% 11.1%
no SP (2000–07) N 475 57 532
% 89.3% 10.7%
All N 818 86 904
% 90.5% 9.5%Malaria Journal 2008, 7:234 http://www.malariajournal.com/content/7/1/234
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during the course of her pregnancy; three antenatal visits
appear to be critical.
Women who undergo only two visits and do so early have
a low probability of a second SP dose because they do not
comply with the ANC schedule and only come back for
delivery. Those of them who do end up with two SP doses
do so late into their pregnancy, which questions the real
utility of the intervention in these cases. For women seen
three times or more, the benefit of an early first SP dose on
having a second dose is seen earlier in pregnancy as the
number of visits increases. This also means that for these
women, the earlier the first visit the more stable the prob-
ability of a second SP dose remains over time; 20 weeks
appears to be the time of the first SP dose beyond which
the chances of having two doses of SP start falling (and
more rapidly so if the first visit is late). Of note, the
median weeks of first ANC visit and first SP dose here were
week 20 and 22, respectively, and 34% of these women
had their first SP dose by week 20. Ideally, women should
have their first ANC visit at nine weeks and have at least
four visits in order to maximize the probability of two SP
doses. With fewer than four ANC visits, the probability of
two SP doses decreases rapidly (see Figure 4). The number
of ANC visits is an important element to properly predict
optimal conditions to receiving two doses of SP. Lastly, it
should be noted that only 56% of women received one
dose in the second and one in the third trimester as rec-
ommended by the WHO.
These data should be compared to other settings, and the
model developed could be used to analyse and optimize
service delivery at other sites. The effects of this interven-
tion on mothers and babies are more difficult to assess.
Mlomp is in an area of moderately intense malaria trans-
mission where women in childbearing age are exposed to
the risk of malaria – approximately one third of the
malaria cases in Mlomp are 15–45 years old [8,9].
The deployment of IPTp-SP did not result in a reduction
of maternal malaria, but cases were few both before and
during the deployment of IPTp-SP. Placental malaria was
not assessed. Over the study period malaria prevalence
has declined in Mlomp. During 2000–2003, ca. 13,000
antimalarial treatments were administered per annum at
the district health centre, compared to ca. 8,000 for 2004–
2006. Similarly, the slide positive rate of patients present-
ing with fever declined from 44% to 28% (unpublished
data extracted from the dispensary registers). Other con-
current interventions may have contributed: (i) the stag-
gered implementation from 2000 of the
artesunate+amodiaquine combination for parasitologi-
cally confirmed falciparum malaria [9] replacing quinine
or chloroquine on presumptive diagnosis [8]; (ii) the dis-
tribution in the village of an average of 250 insecticide-
treated bed nets (ITNs) per year since 2002, although
there is no data on the use of ITNs. It is important to note
that, even in this area of moderate transmission, maternal
malaria tends to occur on or before month four of preg-
nancy, i.e. earlier than the first antenatal visit and the time
at which IPTp is normally started here. This underlines the
need for combined preventive measures including ITNs
[17].
In this population, the prevalence of LBW in the absence
of IPTp (years 2000–2003) was 10.8%, compared to
14.4% in the aggregate placebo arms of the studies
included in ter Kuile et al systematic review [5]. Here, the
prevalence of LBW dropped to 7.7% during IPTp deploy-
ment, irrespective of the number of SP doses (a 29%
reduction) and was 7.1% for women who had two SP
doses (vs. 10.7% if no IPTp, i.e. a 33.5% reduction). While
statistically not significant, these results are clinically rele-
vant, and are consistent with the 28.6% reduction overall
found in the systematic review (36.9% when the analysis
excluded the studies with concomitant use of ITNs). How-
ever, birth weight is multifactorial. There is indication of
improved follow up of pregnancies in Mlomp. The pro-
portion of pregnancies with three or more antenatal visits
increased from 64% in 2004 to 78% in 2007; 46% of
women seen at the ANC had a recorded pregnancy out-
come in 2000 compared to 74% in 2006. In this setting,
LWB was not significantly influenced by gravidity.
This paper provides also interesting data on pregnancy
outcomes and defects. Obvious malformations in dead
babies were seen in 1.35% of pregnancies with a recorded
outcome (an incidence which is similar to that in devel-
oped countries [18]), with no difference between pre- and
during IPTp. There was a preponderance of defects of the
central nervous system and club foot; this could be due to
the fact that these are more obvious defects to detect or
could have occurred by chance (skewed distributions in
limited series). Indeed proper training of health personnel
to identify and describe malformations in a standardized
way would be beneficial.
In conclusion, the implementation rate of IPTp-SP was
very high in this rural clinic in south-western Senegal due
to highly motivated personnel and good attendance and
compliance by pregnant women. The record keeping sys-
tem in place lends itself to data extraction and linkage.
Optimal conditions for compliance to two SP doses could
be modelled, and the model could be applied to other set-
tings. The prevalence of LBW was lower by 29% during
IPTp implementation years, but this effect was not statis-
tically significant and could have other explanations.
Effects on maternal malaria could not be demonstrated in
this area of moderate malaria transmission and ACT
deployment, but placental malaria was not studied. PolicyPublish with BioMed Central    and   every 
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makers should consider the merits and cost-effectiveness
of IPTp deployment in areas of decreasing malaria trans-
mission.
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